Before summer's end, the medicalimaging community can expect to get its first look at a prototypeof Advanced NMR's long-awaited dedicated magnetic resonance mammographysystem. Advanced NMR is planning to unveil the system in the firsthalf of September,
Before summer's end, the medicalimaging community can expect to get its first look at a prototypeof Advanced NMR's long-awaited dedicated magnetic resonance mammographysystem. Advanced NMR is planning to unveil the system in the firsthalf of September, according to William Voorheis, president andCOO of the Wilmington, MA, company.
The yet-to-be-named product will be based on superconductingmagnet technology, with the magnet manufactured by British supplierMagnex. The scanner's field strength will be between 0.5 and 0.8tesla, Voorheis told SCAN. To the uninitiated, its outward appearancewill be similar to that of a standard MRI scanner.
Patients will be scanned while in a prone position, which enablesbreasts to be extended in a technique similar to that used indedicated breast biopsy tables marketed by Fischer Imaging andLorad.
The system's field-of-view will cover the entire breast, backto the chest wall and axilla. Procedures will take about 10 minutes.
Low cost and user-friendliness were primary design considerations,according to Voorheis. The system will cost less than $450,000and will be compact and light enough to be installed in private-practiceoffices. Voorheis envisions that sales of the unit will be aimedat the x-ray mammography market.
"Our whole approach is Clinton-friendly," he said.
The diagnostic role to be played by the system is expectedto evolve over time. Initially, it will most likely be used asan adjunct to x-ray mammography, particularly for ambiguous anddifficult-to-diagnose cases, Voorheis said. If the most optimisticscenarios for MRM prove true, the technology could lead to a reliable,noninvasive way to differentiate benign from malignant breastlesions, he said.
Advanced NMR has acquired images from the system and hopesto make the first installation of the unit by the end of thisyear.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.